Jason Hannon joined Mainstay Medical as Chief Executive Officer and as a Director in October 2017. Mr. Hannon has extensive experience in the medical devices industry, particularly in the areas most critical to the future success of Mainstay: commercialization of new products, penetration of new markets, product innovation, strategic and financial planning, raising capital, regulatory and clinical management, and the building of a high-performance culture.
Mr. Hannon previously served as President and Chief Operating Officer of NuVasive (NASDAQ:NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions. He helped grow NuVasive from a small U.S.-centric business with a handful of products into the third largest spine company in the world. During his 12 years at the company, and prior to becoming COO, Mr. Hannon led the international business, was responsible for business development and strategy, and also served as general counsel. During his tenure, the company’s commercial presence was expanded globally to more than 40 countries, revenue grew from $61M to almost $1 billion, and the product portfolio expanded to over 100 products.
Mr. Hannon has a JD degree from Stanford University Law School and a BA degree from the University of California, Berkeley.
Chief Operating Officer
Prashant Rawat has worked more than 20 years in active implantable medical device companies (Guidant, CVRx, CSF Therapeutics) and brings broad experience in managing global engineering teams and achieving international regulatory product approvals. Mr. Rawat is responsible for all research and development, coordination of manufacturing and distribution, clinical operations, the Quality Management System, and expansion of the company’s Intellectual Property portfolio.
Mr. Rawat’s extensive international experience in the medical device industry includes building internal R&D teams and relationships with foreign institutions and companies for joint research, product development and manufacturing. He also has broad experience in guiding new technology through the clinical and regulatory processes in Europe, Asia and the United States. While Technology Fellow and Manager of the Advanced Technology Group at Boston Scientific’s Cardiac Rhythm Management group, he was responsible for development of the world’s first implantable long-range telemetry system. Since then, he worked as an advisor to CVRx, a private neurostimulation company developing an implantable device for treatment of high blood pressure, and was VP Research and Development at CSF Therapeutics, a venture capital-backed spinoff from the Cleveland Clinic developing a novel invasive therapy to improve blood flow in stroke victims.
Mr. Rawat has a Bachelor of Engineering in Electronics Engineering and Telecommunications from the Maharaja Sayajirao University, Gujarat, India, and a Master of Science in Electrical Engineering and Applied Physics from Case Western Reserve University, Ohio, U.S. He is the inventor on over 25 patents and patent applications.
Chief Financial Officer
Mr. Onaitis has worked with dynamic healthcare businesses for 20 years, ranging from global multinationals including Biogen Idec and Elan Pharmaceuticals, to innovative specialty pharmaceutical companies such as Ignyta, Trius Therapeutics, and Somaxon Pharmaceuticals. He most recently served as Chief Financial Officer of Cidara Therapeutics (NASDAQ: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies. During his tenure at Cidara, the company raised over $185 million and successfully progressed its lead program into late-stage clinical trials. Cidara is one of four publicly-traded healthcare companies at which Mr. Onaitis has been a senior executive. His experience includes building finance teams, leading numerous public and private financings, mergers and acquisitions and strategic collaborations, and the management of finance, accounting, business development, manufacturing, legal, and human resource functions.
Mr. Onaitis holds a J.D. from Stanford Law School and a B.S. in mechanical engineering from Carnegie Mellon University.
Jan Pieter Heemels
Vice President Clinical and Scientific Communication
Jan Pieter Heemels has in excess of 30 years of international experience in active implantable medical devices (Cordis, Guidant, Boston Scientific, Spinal Modulation), including over a decade in Neuromodulation. He is currently responsible for clinical and scientific communication in partnership with leading clinicians and their societies and alignment of the companies’ clinical, commercial and reimbursement strategies.
Mr. Heemels’ broad international experience includes managing new product definitions, clinical trials, sales and market development for Cardiac Rhythm Management products (implantable cardiac pacemakers and defibrillators) in Guidant and Boston Scientific. Subsequently he was a consultant to privately held start-up companies in Neuromodulation (Spinal Modulation) and medical imaging for urology (Advanced Medical Diagnostics). Since joining Mainstay in early 2011, he has been instrumental in preparing the company and medical community for commercialisation of ReActiv8.
Mr. Heemels holds a Master of Science degree in physics from the VU University in Amsterdam and a Master of Business Administration degree from the University of Minnesota. He is named inventor on 12 key patents and patent applications in the field of biomedical engineering, including neuromodulation.
Vice President Clinical Affairs
Diane Burnside has over 37 years of experience in the medical device industry, with eleven years specifically in active implantable medical devices. Ms. Burnside brings broad experience in clinical leadership, including strategic direction, design and execution of clinical programs to obtain CE Mark certifications and PMA approvals. Her responsibilities comprise planning and implementing strategy, procedures and practice in clinical programs to gain global regulatory and reimbursement approvals.
Ms. Burnside has worked in start-up and large multinational companies, contributing to all phases of product development including research, pre-clinical and clinical evaluations, post-market studies, post-approval studies and international clinical programs. Ms. Burnside recently served as Vice President of Clinical Affairs at Kspine, where she was instrumental in setting up and managing an international clinical trial for studying the effects of a spinal implant for the treatment of pediatric scoliosis. Previous to that, she held clinical leadership positions at Neurostream/OttoBock, Uromedica, Medtronic Neurological division and Boston Scientific. She has overseen clinical programs in the United States, Europe, Australia, and Canada that have led to the approval of multiple products. Ms. Burnside has been involved in 5 PMA approvals, including three panel meetings, of neuromodulation for Parkinson’s disease, and cardiologic, vascular and urological stents.
Ms. Burnside holds an Applied Science degree from the University of Minnesota.
Country Manager Germany
Boris Deutschmann joined Mainstay Medical as Country Manager Germany in March 2020 and joins with 15 years’ sales experience within the pharmaceutical and medical device industry with focus on pain therapies. With 10 years’ experience in the Neuromodulation area Mr Deutschmann was active within the Neuromodulation division of St. Jude Medical (now Abbott) and Nevro Germany. During his time at Nevro, Mr Deutschmann was responsible in establishing the therapy and patient concepts and formed one of the most successful teams worldwide, increasing business for Nevro to a market share of 30% for RC-IPGS and establishing the HF10 Therapy in Germany. Mr Deutschmann brings extensive knowledge of the international Neuromodulation business and launching new products and therapies.
Mr Deutschmann studied Economics at the Klett-Academy and Biology at the Carolo Wilhelmina University in Braunschweig with a Diploma degree.
Vice President UK & Ireland
James Knibbs joined Mainstay Medical as Vice President UK & Ireland in March 2020 and joins with extensive experience of Sales leadership in implantable medical devices. Working in roles of increasing responsibility with Vygon, Stryker and more recently Nevro, James has demonstrated an exceptional track record of building elite sales teams and consistently delivering exceptional results. During his time at Nevro, James helped build the therapy from the ground up and led a UK team of 16 to three consecutive International Team of the Year awards and reached 50% market share in 5 years. Most recently Mr Knibbs was Senior Director of Western Europe with Nevro and was responsible for rebuilding and reigniting the region through strategy design and implementation, talent development and sales execution in order to drive market share growth with both direct and distributor sales teams.
Mr Knibbs holds a BA Hons in Accounting & Finance from Leeds University and has completed the Executive Development Program at Wharton Business School, Philadelphia.